Feasibility of the Maastro Applicator in Rectal Cancer

Quality of Life Clinical Trial

Official title:

Introduction of the Maastro Applicator for Endoluminal Boosting in Rectal Cancer: a Pilot Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06087718
• Other study ID #: Feasibility Maastro applicator
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 2024
• Est. completion date: April 2031

Study information

• Verified date: May 2024
• Source: Maastricht Radiation Oncology
• Contact: Ann Claessens
• Phone: +31884455863
• Email: ann.claessens[@]maastro.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this interventional pilot trial is to confirm that Maastro endoluminal HDR ( High Dose Radiation) contact brachytherapy boosting is feasible and may increase the chance of functional organ sparing of the rectum in patients with rectal cancer. Participants will be treated with chemoradiotherapy and an endoluminal boost with the Maastro applicator.

Description:

The goal of this clinical trial is to confirm that Maastro endoluminal HDR contact brachytherapy boosting is feasible and may increase the chance of functional organ sparing of the rectum in patients with rectal cancer. If at least 7 out of 10 planned Maastro applicator treatment series (3 fractions per series) can be conducted successfully from a procedural point of view the treatment will be considered feasible. The study intervention will be similar to the study treatment of arm B of the OPERA trial. Opposed to the treatment in arm B of the OPERA trial, the endoluminal boost will be given using HDR brachytherapy with the Maastro applicator instead of a CXRT (Contact X-ray Radiotherapy) device. The dose profile of the Maastro applicator is similar to the dose profile of CXRT device. As in the OPERA trial patients will be stratified based on tumor size. As the diameter of the treatment field of the largest Maastro applicator (there are two sizes) equals 2.5 cm we will stratify for tumor diameter < 2.5 cm v ≥ 2.5 cm. In the OPERA trial patients were stratified for a tumor diameter of < 3.0 cm v ≥ 3.0 cm as currently the largest applicator diameter for the CXRT device is 3.0 cm (currently available applicators: 2.0, 2.5 and 3.0 cm). The endoluminal boost will consist of 3 fractions with a dose equivalent to 30 Gy per fraction prescribed at the surface of the applicator. The 3 boost fractions will be delivered over a 4-week time period (week 1-2-4). Conform OPERA protocol, patients with a tumor size < 2.5 cm will receive an upfront endoluminal HDR contact boost followed by concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days). Patients with a tumor size ≥ 2.5 cm will first undergo concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days) to first shrink the tumor and will receive the endoluminal HDR contact boost afterwards in order to eventually fit the tumor surface in the surface of the Maastro applicator.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: April 2031
• Est. primary completion date: April 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• = 18 years of age and capable of giving informed consent.

• Adenocarcinoma of the rectum classified cT (clinical Tumor) 2-3b, < 5 cm largest diameter and < ½ circumference (MRI staging), N0-N1 (any node < 8 mm diameter), M0

• Operable patient

• Tumor accessible to the Maastro applicator with a distance from the lower tumor border to the anal verge =10 cm

• No comorbidity preventing treatment

• Adequate birth control for women of child-bearing potential

• Follow-up possible.

Exclusion Criteria:

• Tumor extending into the anal canal.

• Stop of anti-coagulants (except =100 mg aspirin/day) is medically contraindicated.

• Presence of coagulation disorder resulting in an increased bleeding risk.

• Prior pelvic radiation therapy (excluding the abovementioned neoadjuvant treatment).

• Prior surgery or chemotherapy for rectal cancer (excluding the abovementioned neoadjuvant treatment).

• Inflammatory bowel disease (IBD).

• (Systemic) treatment possibly causing rectal or genitourinary toxicity for a separate active malignancy.

• World Health Organization performance status (WHO-PS) = 3.

• Life expectancy of < 6 months.

• Pregnant women.

Related Conditions & MeSH terms

• Brachytherapy
• Complete Response
• Feasibility
• Proctitis
• Quality of Life
• Radiation Proctitis
• Radiation Toxicity
• Rectal Cancer
• Rectal Neoplasms
• Toxicity

Intervention

Device:
• Maastro applicator
The dose profile of the Maastro applicator is similar to the dose profile of a CXRT device. Patients will be stratified based on tumor size. The cut-off is set at the maximum diameter of the treatment surface of the Maastro applicator. The boost consists of 3 fractions with a dose equivalent to 30 Gy per fraction prescribed at the surface of the applicator. The 3 boost fractions will be delivered over a 4-week time period. Patients with a tumor size < 2.5 cm will receive an upfront boost followed by concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days). Patients with a tumor size = 2.5cm will first undergo concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days) and will afterwards receive the boost.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Maastricht Radiation Oncology	Varian Medical Systems

References & Publications (3)

Bellezzo M, Fonseca GP, Verrijssen AS, Voncken R, Van den Bosch MR, Yoriyaz H, Reniers B, Berbee M, Van Limbergen EJ, Verhaegen F. A novel rectal applicator for contact radiotherapy with HDR 192Ir sources. Brachytherapy. 2018 Nov-Dec;17(6):1037-1044. doi: 10.1016/j.brachy.2018.07.012. Epub 2018 Aug 16. — View Citation

Bellezzo M, Fonseca GP, Voncken R, Verrijssen AS, Van Beveren C, Roelofs E, Yoriyaz H, Reniers B, Van Limbergen EJ, Berbee M, Verhaegen F. Advanced design, simulation, and dosimetry of a novel rectal applicator for contact brachytherapy with a conventional HDR 192Ir source. Brachytherapy. 2020 Jul-Aug;19(4):544-553. doi: 10.1016/j.brachy.2020.03.009. Epub 2020 May 6. — View Citation

Gerard JP, Barbet N, Schiappa R, Magne N, Martel I, Mineur L, Deberne M, Zilli T, Dhadda A, Myint AS; ICONE group. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):356-367. doi: 10.1016/S2468-1253(22)00392-2. Epub 2023 Feb 16. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Collecting 3D ultrasound measurements of the gross tumor volume (GTV) and intestinal wall layers at every fraction of Maastro applicator brachytherapy.	These images can later be used for scientific research including (but not limited to): Developing a method for ultrasound guided GTV / organs at risk (OAR) (various intestinal wall layers, neighboring organs) dose reconstruction calculation in rectal cancer. This information is crucial in order to establish adequate dose-response relations for tumor control (Tumor Control Probability; TCP) and normal tissue toxicity (Normal Tissue Complication Probability, NTCP). Insight in the dose-response relations will allow the clinician to understand in which way the treatment to the individual patient should be adapted to increase cure rates and/or minimise additional toxicity.; Developing ultrasound guided treatment planning software (TPS) which allows future individualised treatment planning.	During treatment
Primary	Clinical feasibility of the Maastro boosting technique.	If at least 7 out of 10 planned Maastro applicator treatment series (3 fractions per series) can be conducted successfully from a procedural point of view the treatment will be considered feasible.	During treatment
Secondary	Efficacy of Maastro applicator endoluminal HDR contact brachytherapy boosting in functional organ sparing of the rectum	Percentage of patients with a persistent clinical complete response with good rectal function (no irreversible G2 or higher toxicity that does not respond to treatment) at 3 years.; (number of patients with a complete response AND no persistent G2 or higher rectal toxicity) / (total number of patients) * 100%	3 years follow-up
Secondary	Percentage of planned interventional Maastro procedures that could be conducted successfully from a procedural point of view.	(procedures conducted successfully from a procedural point of view according to the checklist, please refer to appendix A) / (total number of procedures) * 100%	During treatment
Secondary	Duration of the application procedure.	Time from insertion of the proctoscope to finalising removal of the proctoscope in minutes.	During treatment
Secondary	Percentage of patients with G3 or higher rectal toxicity up to 3 months after treatment potentially attributable to endoluminal HDR contact brachytherapy.	Doctor reported CTCEA (Common Terminology Criteria for Adverse Events) v. 5 G3 or higher rectal toxicity not present before the start of treatment and occurring up to 3 months after treatment potentially attributable to endoluminal radiotherapy.; (number of patients with new G3 or higher rectal toxicity up to 3 months after treatment) / (total number of patients) * 100%	3 months follow-up
Secondary	Clinical complete response rate up to 3 years after treatment.	Clinical response will be assessed using the "watch and wait" protocol which is part of standard clinical care at MUMC+ ( Maastricht Medical University Center). Data will be reported at 3 months, 6 months, 1 year, 2 years and 3 years of follow-up.; (number of patients with a cCR) / (total number of patients) * 100%	3 years follow-up
Secondary	Rectal toxicity scored according to CTCAE v. 5 up to 3 years after treatment.	Both patient and doctor reported rectal toxicity scored according to CTCEA v. 5 will be determined before each application procedure, weekly during chemoradiotherapy, 1 week after treatment and 1, 3, 6, 12, 18, 24 and 36 months after treatment.	3 years follow-up
Secondary	Genitourinary toxicity scored according CTCAE v. 5 up to 3 years after treatment.	Both patient and doctor reported genitourinary toxicity scored according to CTCEA v. 5 will be determined before each application procedure, weekly during chemoradiotherapy, 1 week after treatment and 1, 3, 6, 12, 18, 24 and 36 months after treatment.	3 years follow-up
Secondary	Health status and quality of life as measured by QLQ (quality of life questionnaire)-C30 up to 3 years after treatment.	Patients will fill out the validated health status and quality of life questionnaire QLQ-C30 after inclusion (at baseline) and 1, 3, 6, 12, 18, 24 and 36 months after treatment.	3 years follow-up
Secondary	Health status and quality of life as measured by QLQ-CR29 (Colo Rectal) up to 3 years after treatment.	Patients will fill out the validated health status and quality of life questionnaire QLQ-CR29 after inclusion (at baseline) and 1, 3, 6, 12, 18, 24 and 36 months after treatment.	3 years follow-up
Secondary	Health status and quality of life as measured by EQ-5D (EuroQol Five Dimensions Health Questionnaire) up to 3 years after treatment.	Patients will fill out the EQ-5D-5L after inclusion (at baseline) and 1, 3, 6, 12, 18, 24 and 36 months after treatment.	3 years follow-up
Secondary	Long-term rectal functional outcome as measured by LARS 9 Low Anterior Resection Syndrome) score up to 3 years after treatment.	Patients will fill out the LARS questionnaire after inclusion (at baseline) and 1, 3, 6, 12, 18, 24 and 36 months after treatment.	3 years follow-up
Secondary	Local recurrence rate up to 5 years after treatment.	Local recurrence rate is defined as the rate of rectal recurrences at the site of the initial primary tumor. Local recurrence rate will be registered up to 5 years after treatment by consulting the hospital patient file.; (number of patients with a local recurrence) / (total number of patients) * 100%	5 years follow-up
Secondary	Locoregional recurrence rate up to 5 years after treatment.	Locoregional recurrence rate is defined as the rate of recurrences in the rectum and the regional pelvic lymph node areas. Locoregional recurrence rate will be registered up to 5 years after treatment by consulting the hospital patient file.; (number of patients with a locoregional recurrence) / (total number of patients) * 100%	5 years follow-up
Secondary	Metastatic rate up to 5 years after treatment.	Metastatic rate is defined as the rate of distant metastasis. Metastatic rate will be registered up to 5 years after treatment by consulting the hospital patient file.; (number of patients with distant metastases) / (total number of patients) * 100%	5 years follow-up
Secondary	Salvage surgery rate after treatment.	The percentage of patients undergoing salvage surgery will be determined. Both TME and local excision rate will be reported separately and combined. The reason for surgery (e.g. local recurrence, patient's wish, unacceptable toxicity) if available and the pathologic outcome (e.g. pCR) will also be reported for patients undergoing surgery. Salvage surgery rate will be registered up to 5 years after treatment by consulting the hospital patient file.; (number of patients undergoing salvage surgery) / (total number of patients) * 100%	5 years follow-up
Secondary	Overall and disease specific survival rate up to 5 year after treatment.	Both overall survival rate and disease specific survival rates will be reported. Survival rate will be registered up to 5 years after treatment by consulting the hospital patient file.; 100% - (number of patients having died within 5 years after treatment [due to any causes or due to rectal cancer] / total number of patients * 100%)	5 years follow-up
Secondary	The diagnostic value of clinical response assessment using digital rectal examination, endoscopy and MRI after endoluminal radiation boosting using the Maastro applicator.	Clinical response will be assessed using the "watch and wait" protocol which is part of standard clinical care at MUMC+. According to this protocol tumor response is assessed using a digital rectal examination, sigmoidoscopy and MRI (including T2 and DWI). This combined modality approach has been reported to have a specificity of 97% and a sensitivity of 71% for the detection of complete tumor response after neoadjuvant (chemo)radiotherapy. The exact diagnostic value of this multimodality approach has not been validated in the setting of an endoluminal boost with the Maastro applicator. We will evaluate the diagnostic value by relating the test results to a persistent clinical complete response at 1 and 2 years, residual tumor (yes/no) in the resection specimen in case of salvage surgery and a clinical local recurrence in case of refusal of salvage surgery.	during follow-up
Secondary	Complications within the first 30 days after completion of salvage total mesorectal excision (TME) surgery up to 3 years after treatment.	Complications within the first 30 days after completion or salvage TME surgery will be scored according to the classification of surgical complications by Clavien-Dindo (16). Complications will be registered up to 3 years after treatment by consulting the hospital patient file.	3 years follow-up